A Phase 2 Study of Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 26 Jun 2019
Price : $35 *
At a glance
- Drugs Capecitabine (Primary) ; Fluorouracil (Primary) ; Peginterferon alfa-2b (Primary)
- Indications Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- 11 Jun 2019 Planned End Date changed from 1 May 2019 to 1 Dec 2019.
- 31 May 2019 Status changed from active, no longer recruiting to discontinued, according to the results published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 31 May 2019 Results published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).